{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:18:22Z","timestamp":1787426302808,"version":"build-2736575974"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014389","name":"Amarin Pharma, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014389","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000046","name":"Abbott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006520","name":"Edwards","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Concept Medical"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003122","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003122","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Cigarette smoking is among the most well-established risk factors for adverse cardiovascular outcomes. We sought to determine whether icosapent ethyl (IPE), a highly purified form of eicosapentaenoic acid with antiatherothrombotic properties, may reduce the excessive risk of cardiovascular disease (CVD) attributable to smoking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Reduction of Cardiovascular Events with Icosapent Ethyl Trial (REDUCE-IT) was a multinational, double-blind trial that randomized 8179 statin-treated patients with elevated triglycerides and CV risk to IPE or placebo, with a median follow-up period of 4.9 years. Icosapent ethyl reduced the primary composite endpoint [CV death, non-fatal myocardial infarction (MI), non-fatal stroke, coronary revascularization, or hospitalization for unstable angina] by 25% (P\u00a0&amp;lt;\u00a00.0001). In the current analyses, the effect of IPE was evaluated in REDUCE-IT using post hoc analyses based on smoking history. Groups were classified as current smokers (n\u00a0=\u00a01241), former smokers (n\u00a0=\u00a03672), and never smokers (n\u00a0=\u00a03264). Compared with placebo, IPE use in combined current and former smokers (n\u00a0=\u00a04913) was associated with significant reductions in time to the primary composite endpoint {hazard ratio: 0.77 [95% confidence interval (CI): 0.68\u20130.87]; P\u00a0&amp;lt;\u00a00.0001} and in total events [rate ratio: 0.71 (95% CI: 0.61\u20130.82); P\u00a0&amp;lt;\u00a00.0001]. These benefits remained significant when subdivided into current and former smokers (P\u00a0=\u00a00.04, P\u00a0=\u00a00.005), with reductions in the key secondary composite endpoint (P\u00a0&amp;lt;\u00a00.0001) and in the individual components of CV death or non-fatal MI (P\u00a0=\u00a00.04, P\u00a0=\u00a00.01) and fatal or non-fatal MI (P\u00a0=\u00a00.009, P\u00a0=\u00a00.01), respectively. Benefits were consistent and significant in non-smokers as well. Overall, there were similar estimated rates of first occurrences of primary CVD endpoints in current smokers (23.8%) and former smokers (23.0%) assigned to IPE compared with never smokers on placebo (25.7%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In REDUCE-IT, IPE treatment was associated with a reduced risk of CV events in current and former smokers to levels observed in never smokers. While smoking cessation should always be recommended, these data raise the possibility that IPE treatment may attenuate CV hazards attributable to smoking.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvac045","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T01:57:17Z","timestamp":1660269437000},"page":"129-137","source":"Crossref","is-referenced-by-count":17,"title":["Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1679-2095","authenticated-orcid":false,"given":"Michael","family":"Miller","sequence":"first","affiliation":[{"name":"Corporal Michael J. Crescenz Veterans Affairs Medical Center and Hospital, University of , Philadelphia, PA 19104 , USA"},{"name":"Pennsylvania , Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-2941","authenticated-orcid":false,"given":"Ph Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universit\u00e9 Paris-Cit\u00e9 , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9807-4010","authenticated-orcid":false,"given":"Eliot A","family":"Brinton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Utah Lipid Center , Salt Lake City, UT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9926-2179","authenticated-orcid":false,"given":"Terry A","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7003-4925","authenticated-orcid":false,"given":"Lixia","family":"Jiao","sequence":"additional","affiliation":[{"name":"Amarin Pharma, Inc. , Bridgewater, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-8983","authenticated-orcid":false,"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[{"name":"Department of Medicine, Montreal Heart Institute , Montreal , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-1730","authenticated-orcid":false,"given":"Christie M","family":"Ballantyne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9616-1946","authenticated-orcid":false,"given":"Matthew","family":"Budoff","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, Los Angeles , Los Angeles, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5483-1852","authenticated-orcid":false,"given":"R Preston","family":"Mason","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"2023020208425530600_bib1","first-page":"2337","article-title":"Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990\u20132019: a systematic analysis from the Global Burden of Disease Study 2019","volume-title":"Lancet","author":"GBD 2019 Tobacco Collaborators","year":"2021"},{"key":"2023020208425530600_bib2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1185\/03007995.2013.827566","article-title":"Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review","volume":"29","author":"Athyros","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"2023020208425530600_bib3","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/01.CIR.63.3.546","article-title":"Platelet survival and the development of coronary artery disease in the young adult: effects of cigarette smoking, strong family history and medical therapy","volume":"63","author":"Fuster","year":"1981","journal-title":"Circulation"},{"key":"2023020208425530600_bib4","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jacc.2003.12.047","article-title":"The pathophysiology of cigarette smoking and cardiovascular disease: an update","volume":"43","author":"Ambrose","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2023020208425530600_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2023020208425530600_bib6","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"2023020208425530600_bib7","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023020208425530600_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/vhrm.2006.2.3.251","article-title":"A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels","volume":"2","author":"von Schacky","year":"2006","journal-title":"Vasc Health Risk Manag"},{"key":"2023020208425530600_bib9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"key":"2023020208425530600_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA: results from the 3146 patients randomized in the United States","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"key":"2023020208425530600_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/met.2015.0095","article-title":"Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies","volume":"13","author":"Manna","year":"2015","journal-title":"Metab Syndr Relat Disord"},{"key":"2023020208425530600_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.23876\/j.krcp.20.163","article-title":"Implications of oxidative stress in chronic kidney disease: a review on current concepts and therapies","volume":"40","author":"Verma","year":"2021","journal-title":"Kidney Res Clin Pract"},{"key":"2023020208425530600_bib13","doi-asserted-by":"crossref","first-page":"f5307","DOI":"10.1136\/bmj.f5307","article-title":"Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison","volume":"347","author":"Gagne","year":"2013","journal-title":"BMJ"},{"key":"2023020208425530600_bib14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1160\/TH13-08-0642","article-title":"Unravelling the smokers\u2019 paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y\u2081\u2082 inhibitors","volume":"111","author":"Gurbel","year":"2014","journal-title":"Thromb Haemost"},{"key":"2023020208425530600_bib15","doi-asserted-by":"crossref","first-page":"j5855","DOI":"10.1136\/bmj.j5855","article-title":"Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports","volume":"360","author":"Hackshaw","year":"2018","journal-title":"BMJ"},{"key":"2023020208425530600_bib16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/hrt.49.5.410","article-title":"Influence of cigarette smoking on morbidity and mortality after myocardial infarction","volume":"49","author":"Mulcahy","year":"1983","journal-title":"Br Heart J"},{"key":"2023020208425530600_bib17","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1253\/circj.CJ-19-0323","article-title":"Effects of tobacco smoking on cardiovascular disease","volume":"83","author":"Kondo","year":"2019","journal-title":"Circ J"},{"key":"2023020208425530600_bib18","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/CIRCULATIONAHA.117.031912","article-title":"Cigarette smoking and incident heart failure: insights from the Jackson Heart Study","volume":"137","author":"Kamimura","year":"2018","journal-title":"Circulation"},{"key":"2023020208425530600_bib19","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.amjcard.2019.03.015","article-title":"Relation between cigarette smoking and heart failure (from the multiethnic study of atherosclerosis)","volume":"123","author":"Watson","year":"2019","journal-title":"Am J Cardiol"},{"key":"2023020208425530600_bib20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1741826711411738","article-title":"Nicotine, cigarette smoking and cardiac arrhythmia: an overview","volume":"19","author":"D'Alessandro","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"2023020208425530600_bib21","doi-asserted-by":"crossref","first-page":"e1001515","DOI":"10.1371\/journal.pmed.1001515","article-title":"Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis","volume":"10","author":"Cheng","year":"2013","journal-title":"PLoS Med"},{"key":"2023020208425530600_bib22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/HCO.0000000000000204","article-title":"Smoking cessation and the cardiovascular patient","volume":"30","author":"Prochaska","year":"2015","journal-title":"Curr Opin Cardiol"},{"key":"2023020208425530600_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.atherosclerosis.2015.07.035","article-title":"Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis","volume":"242","author":"Borow","year":"2015","journal-title":"Atherosclerosis"},{"key":"2023020208425530600_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11886-020-01356-4","article-title":"Icosapent ethyl: niche drug or for the masses?","volume":"22","author":"Bazarbashi","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"2023020208425530600_bib25","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023020208425530600_bib26","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation"},{"key":"2023020208425530600_bib27","doi-asserted-by":"crossref","first-page":"102337","DOI":"10.1016\/j.plefa.2021.102337","article-title":"Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability","volume":"173","author":"Sherratt","year":"2021","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2023020208425530600_bib28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1253\/circj.CJ-11-0941","article-title":"Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention","volume":"76","author":"Domei","year":"2012","journal-title":"Circ J"},{"key":"2023020208425530600_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1758-5996-6-85","article-title":"Eicosapentaenoic acid\/arachidonic acid ratio and smoking status in elderly patients with type 2 diabetes mellitus","volume":"6","author":"Okada","year":"2014","journal-title":"Diabetol Metab Syndr"},{"key":"2023020208425530600_bib30","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur Heart J"},{"key":"2023020208425530600_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCULATIONAHA.120.050276","article-title":"Reduction in revascularization with icosapent ethyl","volume":"143","author":"Peterson","year":"2021","journal-title":"Circulation"},{"key":"2023020208425530600_bib32","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/CIRCULATIONAHA.121.056290","article-title":"Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG","volume":"144","author":"Verma","year":"2021","journal-title":"Circulation"},{"key":"2023020208425530600_bib33","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jacc.2021.11.005","article-title":"Consistency of benefit of icosapent ethyl by background statin type in REDUCE-IT","volume":"79","author":"Singh","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023020208425530600_bib34","doi-asserted-by":"crossref","first-page":"e022937","DOI":"10.1161\/JAHA.121.022937","article-title":"Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention: insights from REDUCE-IT PCI","volume":"11","author":"Peterson","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2023020208425530600_bib35","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2022.02.035","article-title":"Prevention of cardiovascular events and mortality with icosapent ethyl in patients with prior myocardial infarction","volume":"79","author":"Gaba","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvac045\/45599154\/pvac045.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/2\/129\/49043724\/pvac045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/2\/129\/49043724\/pvac045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T09:03:22Z","timestamp":1675328602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/9\/2\/129\/6661415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,8,11]]},"published-print":{"date-parts":[[2023,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvac045","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3]]},"published":{"date-parts":[[2022,8,11]]}}}